Repare Therapeutics Inc. (NASDAQ:RPTX – Get Rating) has been assigned an average recommendation of “Moderate Buy” from the eight analysts that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $42.57.
Several brokerages have recently commented on RPTX. Stifel Nicolaus downgraded Repare Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, April 12th. The Goldman Sachs Group began coverage on Repare Therapeutics in a research note on Thursday, March 17th. They issued a “buy” rating and a $43.00 target price for the company. Piper Sandler raised their target price on Repare Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, June 2nd. Finally, HC Wainwright reduced their target price on Repare Therapeutics from $54.00 to $38.00 and set a “buy” rating for the company in a research note on Monday, June 6th.
Shares of Repare Therapeutics stock opened at $14.77 on Tuesday. The business has a 50-day moving average price of $11.44 and a two-hundred day moving average price of $14.10. Repare Therapeutics has a 1-year low of $8.06 and a 1-year high of $35.75. The company has a market cap of $618.77 million, a P/E ratio of -4.81 and a beta of 0.92.
Slaving away for 70 hrs a week as a lawyer in Chicago, I was miserable.
I ran into guys who worked the trading floor at the local exchange. I began trading the same way they did. I started out with $50K (much more than I needed, actually).
I grew my $50K into $5.3M
Repare Therapeutics (NASDAQ:RPTX – Get Rating) last issued its quarterly earnings results on Thursday, May 5th. The company reported ($0.83) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.06. Repare Therapeutics had a negative return on equity of 47.60% and a negative net margin of 1,533.38%. The firm had revenue of $0.41 million during the quarter, compared to the consensus estimate of $2.13 million. Analysts forecast that Repare Therapeutics will post -3.33 earnings per share for the current fiscal year.
In other Repare Therapeutics news, Director Davis Jerel sold 750,000 shares of Repare Therapeutics stock in a transaction that occurred on Friday, June 3rd. The shares were sold at an average price of $12.25, for a total transaction of $9,187,500.00. Following the transaction, the director now owns 44,065 shares of the company’s stock, valued at approximately $539,796.25. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Bvf Partners L. P/Il bought 420,000 shares of the company’s stock in a transaction on Wednesday, May 18th. The shares were purchased at an average cost of $8.50 per share, for a total transaction of $3,570,000.00. Following the transaction, the insider now owns 3,350,950 shares in the company, valued at $28,483,075. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 1,762,075 shares of company stock worth $19,412,565. 30.30% of the stock is owned by insiders.
Several institutional investors have recently bought and sold shares of RPTX. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its holdings in shares of Repare Therapeutics by 9.5% in the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 11,580 shares of the company’s stock worth $165,000 after purchasing an additional 1,002 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of Repare Therapeutics by 5.3% in the 1st quarter. JPMorgan Chase & Co. now owns 25,039 shares of the company’s stock worth $356,000 after purchasing an additional 1,253 shares during the period. DekaBank Deutsche Girozentrale raised its holdings in shares of Repare Therapeutics by 9.8% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 14,600 shares of the company’s stock worth $210,000 after purchasing an additional 1,300 shares during the period. Renaissance Technologies LLC raised its holdings in shares of Repare Therapeutics by 1.6% in the 1st quarter. Renaissance Technologies LLC now owns 88,100 shares of the company’s stock worth $1,255,000 after purchasing an additional 1,400 shares during the period. Finally, Virtus ETF Advisers LLC raised its holdings in shares of Repare Therapeutics by 28.9% in the 4th quarter. Virtus ETF Advisers LLC now owns 8,355 shares of the company’s stock worth $176,000 after purchasing an additional 1,873 shares during the period. 89.66% of the stock is currently owned by hedge funds and other institutional investors.
Repare Therapeutics Company Profile (Get Rating)
Repare Therapeutics Inc, a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Should you invest $1,000 in Repare Therapeutics right now?
Before you consider Repare Therapeutics, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Repare Therapeutics wasn’t on the list.
While Repare Therapeutics currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Read More: Repare Therapeutics Inc. (NASDAQ:RPTX) Receives Consensus Recommendation of “Moderate